Symkevi/Kalydeco cleared for use in young CF patients
The combination is the first available to treat the underlying cause of CF in this patient group.
Read More
Tag: F508del
Vertex to test CF triple combo therapy in Phase III trials
Vertex Pharmaceuticals will begin testing a combination of VX-445, tezacaftor and ivacaftor as a potential treatment for people with cystic fibrosis (CF) in two Phase III studies.
Read More
Vertex’ CF therapy Orkambi cleared for younger patients
European regulators have expanded the scope of Vertex’ Orkambi to include children with cystic fibrosis aged six through 11 who have two copies of the F508del mutation.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
